ARS Pharmaceuticals (SPRY) Free Cash Flow Growth (3y) (2023 - 2026)
ARS Pharmaceuticals (SPRY) Free Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 31.42% |
| 10 | ARS Pharmaceuticals | 571.45 Mn | 370.48 Mn | - | -52.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.71% |
| Dec 31, 2025 | -28.23% |
| Sep 30, 2025 | -93.72% |
| Jun 30, 2025 | -86.47% |
| Mar 31, 2025 | -80.48% |
| Dec 31, 2024 | 13.24% |
| Sep 30, 2024 | 8.47% |
| Jun 30, 2024 | 21.43% |
| Mar 31, 2024 | 17.81% |
| Dec 31, 2023 | -15.53% |
| Sep 30, 2023 | -18.55% |
| Jun 30, 2023 | -44.88% |
| Mar 31, 2023 | -18.11% |